664 related articles for article (PubMed ID: 27692092)
1. Demonstration of the ability of a canine Lyme vaccine to reduce the incidence of histological synovial lesions following experimentally-induced canine Lyme borreliosis.
Grosenbaugh DA; Rissi DR; Krimer PM
Vet Immunol Immunopathol; 2016 Nov; 180():29-33. PubMed ID: 27692092
[TBL] [Abstract][Full Text] [Related]
2. Immunization with a recombinant subunit OspA vaccine markedly impacts the rate of newly acquired Borrelia burgdorferi infections in client-owned dogs living in a coastal community in Maine, USA.
Eschner AK; Mugnai K
Parasit Vectors; 2015 Feb; 8():92. PubMed ID: 25890386
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of a nonadjuvanted, outer surface protein A, recombinant vaccine in dogs after challenge by ticks naturally infected with Borrelia burgdorferi.
Conlon JA; Mather TN; Tanner P; Gallo G; Jacobson RH
Vet Ther; 2000; 1(2):96-107. PubMed ID: 19757556
[TBL] [Abstract][Full Text] [Related]
4. Characterization of recombinant OspA in two different Borrelia vaccines with respect to immunological response and its relationship to functional parameters.
Grosenbaugh DA; De Luca K; Durand PY; Feilmeier B; DeWitt K; Sigoillot-Claude C; Sajous ML; Day MJ; David F
BMC Vet Res; 2018 Oct; 14(1):312. PubMed ID: 30326885
[TBL] [Abstract][Full Text] [Related]
5. Bacterin that induces anti-OspA and anti-OspC borreliacidal antibodies provides a high level of protection against canine Lyme disease.
LaFleur RL; Dant JC; Wasmoen TL; Callister SM; Jobe DA; Lovrich SD; Warner TF; Abdelmagid O; Schell RF
Clin Vaccine Immunol; 2009 Feb; 16(2):253-9. PubMed ID: 19052162
[TBL] [Abstract][Full Text] [Related]
6. Recombinant OspA protects dogs against infection and disease caused by Borrelia burgdorferi.
Chang YF; Appel MJ; Jacobson RH; Shin SJ; Harpending P; Straubinger R; Patrican LA; Mohammed H; Summers BA
Infect Immun; 1995 Sep; 63(9):3543-9. PubMed ID: 7642289
[TBL] [Abstract][Full Text] [Related]
7. Protection against tick-transmitted Lyme disease in dogs vaccinated with a multiantigenic vaccine.
Straubinger RK; Dharma Rao T; Davidson E; Summers BA; Jacobson RH; Frey AB
Vaccine; 2001 Oct; 20(1-2):181-93. PubMed ID: 11567763
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with the ospA- and ospB-Negative Borrelia burgdorferi Strain 50772 Provides Significant Protection against Canine Lyme Disease.
LaFleur RL; Callister SM; Dant JC; Wasmoen TL; Jobe DA; Lovrich SD
Clin Vaccine Immunol; 2015 Jul; 22(7):836-9. PubMed ID: 25972405
[TBL] [Abstract][Full Text] [Related]
9. Synovial lesions in experimental canine Lyme borreliosis.
Susta L; Uhl EW; Grosenbaugh DA; Krimer PM
Vet Pathol; 2012 May; 49(3):453-61. PubMed ID: 22075774
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of antibody responses to outer surface protein (Osp)A and OspC in dogs vaccinated with Lyme disease vaccines.
Camire AC; Hatke AL; King VL; Millership J; Ritter DM; Sobell N; Weber A; Marconi RT
Vet J; 2021 Jul; 273():105676. PubMed ID: 34148599
[TBL] [Abstract][Full Text] [Related]
11. Dogs vaccinated with common Lyme disease vaccines do not respond to IR6, the conserved immunodominant region of the VlsE surface protein of Borrelia burgdorferi.
O'Connor TP; Esty KJ; Hanscom JL; Shields P; Philipp MT
Clin Diagn Lab Immunol; 2004 May; 11(3):458-62. PubMed ID: 15138170
[TBL] [Abstract][Full Text] [Related]
12. Vaccination against lyme disease with recombinant Borrelia burgdorferi outer-surface protein A (rOspA) in horses.
Chang Y; Novosol V; McDonough SP; Chang CF; Jacobson RH; Divers T; Quimby FW; Shin S; Lein DH
Vaccine; 1999 Oct; 18(5-6):540-8. PubMed ID: 10519945
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of OspA vaccination-induced serological correlates of protection against Lyme borreliosis in a mouse model.
Schwendinger MG; O'Rourke M; Traweger A; Savidis-Dacho H; Pilz A; Portsmouth D; Livey I; Barrett PN; Crowe BA
PLoS One; 2013; 8(11):e79022. PubMed ID: 24260146
[TBL] [Abstract][Full Text] [Related]
14. Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs.
Scheckelhoff MR; Telford SR; Hu LT
Vaccine; 2006 Mar; 24(11):1949-57. PubMed ID: 16300863
[TBL] [Abstract][Full Text] [Related]
15. A fluorescent bead-based multiplex assay for the simultaneous detection of antibodies to B. burgdorferi outer surface proteins in canine serum.
Wagner B; Freer H; Rollins A; Erb HN
Vet Immunol Immunopathol; 2011 Apr; 140(3-4):190-8. PubMed ID: 21208663
[TBL] [Abstract][Full Text] [Related]
16. Tick-Tattoo: DNA Vaccination Against
Klouwens MJ; Trentelman JJA; Wagemakers A; Ersoz JI; Bins AD; Hovius JW
Front Immunol; 2021; 12():615011. PubMed ID: 33717102
[TBL] [Abstract][Full Text] [Related]
17. Multiple antigen target approach using the Accuplex4 BioCD system to detect Borrelia burgdorferi antibodies in experimentally infected and vaccinated dogs.
Moroff S; Woodruff C; Woodring T; Sokolchik I; Lappin MR
J Vet Diagn Invest; 2015 Sep; 27(5):581-8. PubMed ID: 26289718
[TBL] [Abstract][Full Text] [Related]
18. Reservoir targeted vaccine for lyme borreliosis induces a yearlong, neutralizing antibody response to OspA in white-footed mice.
Meirelles Richer L; Aroso M; Contente-Cuomo T; Ivanova L; Gomes-Solecki M
Clin Vaccine Immunol; 2011 Nov; 18(11):1809-16. PubMed ID: 21918116
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with meningococcal outer membrane vesicles carrying Borrelia OspA protects against experimental Lyme borreliosis.
Klouwens MJ; Salverda MLM; Trentelman JJ; Ersoz JI; Wagemakers A; Gerritzen MJH; van der Ley PA; Hovius JW
Vaccine; 2021 Apr; 39(18):2561-2567. PubMed ID: 33812741
[TBL] [Abstract][Full Text] [Related]
20. OspA immunization decreases transmission of Borrelia burgdorferi spirochetes from infected Peromyscus leucopus mice to larval Ixodes scapularis ticks.
Tsao J; Barbour AG; Luke CJ; Fikrig E; Fish D
Vector Borne Zoonotic Dis; 2001; 1(1):65-74. PubMed ID: 12653137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
